Related Experiment Video
Updated: Jun 1, 2025
04:41
Application of the En Bloc Concept Combined with Anatomic Resection in Laparoscopic Hepatectomy
Published on: March 10, 2023
1.1K
Macrotrabecular-Massive Hepatocellular Carcinoma: A Case Report.
Raphaël Eftimie Spitz1, Simona Manole2, Teodora Surdea-Blaga3
1Department of Clinical Immunology and Allergology, Iuliu Hatieganu University of Medicine and Pharmacy of Cluj, Cluj-Napoca, ROU.
Cureus
|January 21, 2025
Summary
Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC), an aggressive liver cancer subtype, presents unique challenges due to its occurrence in non-cirrhotic livers and poor response to standard treatments. This case highlights the urgent need for novel therapeutic strategies for MTM-HCC.
Area of Science:
- Hepatology
- Oncology
- Molecular Pathology
Background:
- Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is a rare, aggressive subtype of liver cancer.
- Unlike typical HCC, MTM-HCC can occur in non-cirrhotic livers, posing diagnostic and therapeutic challenges.
Observation:
- A 35-year-old male presented with epigastric pain, fatigue, and hepatomegaly.
- Imaging revealed a large hepatic mass with portal vein thrombosis and metastases.
- Histopathology confirmed MTM-HCC.
Findings:
- The patient received standard treatment for advanced HCC (immune checkpoint inhibitors and anti-angiogenic agents).
- Disease progression occurred after four cycles, leading to a rapid decline and death.
- MTM-HCC exhibits distinct molecular and histological features contributing to its aggressive nature and poor prognosis.
Implications:
- This case underscores the aggressive behavior and limited treatment responsiveness of MTM-HCC.
- Heightened clinical vigilance is crucial for early detection, especially in younger patients with atypical liver disease symptoms.
- Developing targeted therapies and further research into MTM-HCC molecular characteristics are essential for improving patient outcomes.
